Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is good coverage and an excellent amount of views on the article. It will always take a little bit for such stories to get beyond the journal. Further, this is a UCLA story, not an NWBO story. Yes, it is DCVax-L and one should say that, but if people push this as a “small stock” story, they will snuff out interest.
Tell them, if you are excited about it and taking journalists, that this is a brain cancer breakthrough, diligent researchers at UCLA, etc. Do not mention a penny stock any stock ticker, or shorts or stock manipulation. These are words that make such stories go poof.
You sound like a villain in a cartoon with your ridiculous condescension.
Advent is only the CDMO. They are licensed to deliver the product in the UK. It’s not yet an approved product for marketing but can only be locally created for compassionate use. Advent is not the owner of anything but a contract and a small lease and its own CDMO business.
It takes a while for news like the Nature article to get out there. There are the followers and there are many, many more people still completely unaware.
It’s a penny stock. By general policy they don’t cover or invest here. That can be resolved. It’s not “proof” of anything. It has to do with the market. People looking for unusual value dig where others can’t.
There is nothing corrupt or greedy here. If anyone could or should say that, maybe it’s you. But as I said, my sense of you is that you are a messed up individual looking for attention. And you manufacture importance here to garner that attention. I hope you can get some help.
I understand you claim to not care and make grandiose claims about yourself and the things you claim to be doing. But the reality is, and it becomes quite obvious when people who clearly can see what you are and are about, that you’re deeply deluded and not quite right. So popping the bubble of fake reality you manufacture here about yourself is a part of the process of addressing the false notions you perpetuate about yourself and by implication the company and DCVax-L. The reality is, you are irrelevant and have nothing real to say here. You simply seek attention for yourself. It’s messed up and really you need help it sounds like.
Funny from you. The truth is, you and I know, I’m right. You need to go find something more productive for yourself. This is not a good use of your time and you’re basically losing your mind. Figure out something productive to do with your life.
It really doesn’t have to be deduced. The University has said so clearly when it refers to ATL-DC trials as DCVax-L and same with Dr. Liau. Even this paper says it is licensed to NWBO, clearly indicating it is DCVax-L. But so long as there is a generic reference and these fraudsters can get away with intentionally sowing confusion, they will do so, because for them, such activity is plausibly deniable and profitable.
Thanks @metacollectiveG, This Nature article has been peer-reviewed. I really like this part about $NWBO & it confirms that #DCVax = ATL-DC. $NWBO has licensed the DC Vaccine technology from UCLA under the trademark name of DCVax: “Linda M. Liau is a member of the Scientific… https://t.co/qyVgE0R7nA pic.twitter.com/tQgPb6buJN
— ATLnsider (@ATLnsider) May 8, 2024
The reality is you have PR’s from UCLA referring to trials using ATL-DC as DCVax-L, countless presentations by Dr. Liau presenting these results early, within her discussion of DCVax-L, clearly referring to it as the same vaccine, and numerous discussions everywhere confirming that fact. Because it is not a sponsored trial, they are simply using the pre-branding, generic descriptor for what has become labeled DCVax-L when NWBO is the sponsor.
But we realize with your desperation, having lied for years and years, you can’t accept that DCVax-L is still being very beautifully validated by UCLA on an ongoing basis and now has affirmation in Nature, with astonishing results. I understand that this makes your brain hurt. But reality can do that to people who live in a state of non-stop denial.
This is a problem for people who cannot accept reality. But reality is materializing, right before your eyes. Get ready for more reality, because it is coming. You can bet this data was and will be part of future applications. And Dr. Liau is on the SAB, so you can expect she will be there to explain as well.
I simply don’t appreciate a lucid nut stalking investors and the company for made up reasons that are absurd.
No one who was a responsible such person, would be posting as you do here, absent serious mental illness. So I seriously doubt you ever tell the truth at this point. I believe you have a condition of some sort. No one would be on this obscure board, claiming they are a government official, claiming they were a brain tumor patient, but oops, never a patient who got DCVax-L or was ever even considered for this trial, who writes to the MHRA about Kings College but in regard to this trial because their doctor they claim, incoherently, first was concerned they might have GBM, but then discovered they didn’t…
And oh, I used to be a top
Government official and soldier and blah, blah, blah… your story makes zero sense.
This is the thing about brain injuries, people can seem normal, but they have something wrong and they don’t know it, and they otherwise function normally, and it’s impossible to deal with them. I’m sorry for your brain injury. But it has nothing to do with us or this company. You’re basically just attention seeking every day here.
You were not in the trial. You began here by insinuating that you were; you went to the MHRA apparently, or so you suggested, implying that there was something wrong with the trial and that you were a patient at King’s college, again, falsely insinuating that you had unknown information about this trial. You came here after you struck out there, and continue to insinuate, falsely, that you know information you do not know and you attack investors, belittling them based on all of the above, implying that your claimed military experience and CLAIMED experience in governmental ministries in the UK further again inform your critique here, always insinuating, often asserting new, bizarre notions that you claim give you special insights but, generally speaking, none of it is relevant.
You spend your days here because apparently your harassing of the King’s College personnel and his research hospital and institution went nowhere.
You appear to be attention seeking, nonstop. And you do it through negativity.
And there are people who have been stalked here, your behavior is not unlike such people, so while I have no idea if you are that person, I also would not be surprised if you were.
Nonsense. People are excited to see good research using DCVax-L that is most obviously a huge breakthrough.
You really have no business stalking this company or its investors, with all of your fake stories that have absolutely nothing to do with NWBO.
Nature can take a really long time even with breakthrough papers. I have seen it before. Also, NWBOhas nothing to do with the article, it is UCLA and Nature.
She was a VC and she created the forbear company to allow for this product to be made by a CDMO because there was not one in the space. It saved them from having to build a factory at that time which is what destroyed the only other dendritic cell manufacturer previously.
The current company leases space from NWBO and manages NWBO’s own factory. They provide expertise and manpower, but NWBO also bought Flaskworks and expects to buildout the rest of the factory with Flaskworks machines. Now if they outsource the labor, in their own factory, that is a level of flexibility that is admirable.
Further, they received regional financing authority finance to build Sawston to its current level. It was conditional on providing CDMO services to researchers and small companies that also otherwise would not have the resources to build and staff a manufacturing facility, which is often what literally kills these companies. The deal allows Advent to provide those services on behalf of NWBO at NWBO’s built factory, which is a kind of risk shifting and symbiosis again that makes lesser resources go further and do more.
It sounds good to make these ridiculous claims by shorts. You just have to fail to lay out all the facts and make it sound like something it definitely isn’t.
You were never ever in the DCVax-L, you were never considered for it, you never received it, yet you falsely claim to have information about it and to harass investors AND regulators AND King’s College, and you accuse investors of not being well when you were the one who literally was not well.
OK.
You have no business here. You previously admitted you never were part of this trial. You have no information about this trial. You are pretending to be various things from a patient, who was rejected from the trial, to a complainant against King’s College and now you’re claiming to have been a regulator.
Personally, I think you’re an obsessed crazy person with just enough coherence and psychopathy, to keep your little scam here going. But the reality is you have zero information. And you keep trying to fool retail investors otherwise.
The company “plants” nothing. Quit it with your fake short nonsense. If the company is “planting” stuff, go to the SEC and get them put into jail. But you and I know you know that you can’t. All you can do is post false garbage here and pretend to be in the know and hope some nine will believe you.
There is no one plan. All of these trials are driven by individual doctors and companies seeking funding and doing their thing and justifying it by their own research. There’s no single plan. What are you referring to with SWOG? There is no great conspiracy. That is not how this works.
Not really a big deal. Completely election driven. As soon as the election is over, assuming he wins reelection, it will be renewed or renewed in the lame duck period so the next President, whoever it is can claim credit.
https://www.usatoday.com/story/opinion/voices/2024/05/05/biden-cancer-moonshot-initiative-congress-funding/73525016007/
Absolutely. It can happen. We’ve seen it happen. But I don’t count on markets to operate normally at these levels. In fact, I count on them NOT to operate as they are supposed to in order to find unusual opportunities. We know shorts and MM’s scratch each other’s backs and so too do some writers in this space get involved in that nonsense. Success with a deep financial meaning is the ultimate validator. Sometimes it had to have immediate meaning or shorts are going to play with longs to get as much of the value for themselves as they can.
No, just pushes aside the shot piled on the stock for years.
You could say the same for approval by regulatory agencies in your world. Quite frequently approval leaves a stock flat or even going down these days, but the undeniable fact is, that company has gone from pre-revenue to commercial. The best example I can give is Regeneron. After approval it stayed flat for around a year. Was it irrelevant that the FDA approved what became their most important drug approval? Obviously NOT.
The markets are often off, misinformed and unable to judge the future because of shorts and their immense work to misinform the market.
Big events that change the narrative of a drug and company can be something a stock market might not note but every competitor and potential partner might take immense interest in and that can open the door to negotiations that can be quiet, take a while and change the false direction of things that had been set by false narratives told over and over and over again by interests and people who had contrary interests and far more immediate resources.
They don’t have customers that are remotely close to commercialization, so they do not have the technology, regardless of claims. They are CDMOs, their job is to claim they can do it, then, when they get paid, figure it out. Not the same situation at all.
Funny when you laugh. It usually means the opposite. NWBO is not a CDMO. I do not expect them to enter that space.
Yes, Flaskworks was picked up for a song, because at least for now, NWBO has a huge head start on this particular segment of immunotherapies.
The notion that there are others with far more advanced technology in this particular space is not true. Yes, there are CDMO companies that help other companies just like Advent and its predecessor. Of course there are. But this is the only company going commercial in this space with automation and dendritic cells are a particular, sticky animal. No one else is advanced or has debugged any technology remotely similar for automating a process as complicated as this though I am sure you’ll find some random webpage making such a claim. It’s just not true, and the only company out there has helped with this technology and is likely locked under contract.
The reality is, even those companies that claim t have automated car-t processes have not yet had their technologies fully validated or solves the problem that currently leaves those companies unable to meet demand and with extremely high costs, regardless of claims to the contrary.
But yeah, laugh all you want. It doesn’t change reality. It’s empty.
I agree it was picked up for a song.
Looks like a positive sign of their expectation of going commercial shortly.
Eventually. Narratives never immediately change price. This is just your way of trying to steer the conversation back to nonsense. A change in narrative can be quite subtle after years and years of misinformation.
Attempts to misdirect and steal thunder are always noticed, thank you very much.
Despite your deep desire to MISDIRECT, what all the shorts do around here… your fraud is obvious.
Nonsense. Most of the debt at this level is exactly the same. It has not been “disastrous” for shareholders, their loans have not been in huge amounts. And as I said, they put off financings of course with fingers crossed that something better will happen just ahead and they delay immediate reliance on shares.
As for your nonsensical claim that this has to do with “Toucan”, that’s just more short nonsense. That has absolutely nothing to do with partnerships except this… they can’t take it cheap given the serious interests involved that won’t sell it cheap. Yes, THAT keeps a deal at a cheap valuation from happening. It can also lead to shorts, in the interest of taking a company cheap, to short the crap out of such companies to convince them that there is no value there and they are its only hope. But the fight against such interests is actually great for shareholders in the long-run though it always sucks in the short term because near do wells always want to pretend they are white hats rather than black hats and then to shift blame on the executives for “keeping the valuation low”. But the increasing desperation can be heard in the increasing posts, despite this being a very quiet stick. The activity of shorts is CONSTANT and LOUD.
Let’s be clear what my post originally said. It said it will change the narrative. I did not say it automatically and immediately changes “the price”.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174340836
Not true if the capitalization of the principal is delayed and it gives them more time to have events that could change the valuation.
My sense is that to a large degree, the day-to-day at these tiny biocaps is to push forward the dates of recognition of certain full capital costs, with the hope that the capital context will radically change. It’s therefore still leverage until it is paid off.
I have pointed out before that Regeneron stayed flat after its first approval. But the increasing revenue was undeniable. Within a year it started to climb. But before that, the validation should get this to a more level range of valuation.
I know there are people who do not want this, whatever their reasons. And I can’t predict price anymore than the can. But I can counter opinions that give price predictions as a given. No one saw that price pop to $2.51. NO ONE. So don’t tell me the wise guys around here know at all what they are talking about.
It’s not “academic”. They already have production. Approval means revenue. Nature means broader validation.
Where did that post say anything about LP or geniuses? I missed it.
I understand some have certain expectations and I recognize that this indeed does happen. But no one can really say. It depends on a lot of factors. Predictions either way have mostly been wrong. When it hit $2.51 and stayed about $1.50 and $1.25, whiffs were sure it must go down immediately. Of course, what has hurt is the non-stop silence, and the normal context where a lot of people pile out pre-approval, just in case. It’s a common thing to see price go down in the run-up to an approval and then to take off.
As I said, you have potentially incredible results to publish in a journal like Nature. That will transform narratives. What does that mean? It means a lot more speculation on deals and buyouts. That transforms the hunger for the stock, especially one so undervalued.
But yeah, could pop and then go back down. Just about anything can happen in microcap land. If they literally had hens who laid golden eggs, probably there would be piles of skeptics trying to short and talk down the process, first saying no such thing existed, then claiming that they would upset the market price for gold and therefore it’s very bad thing.
The shorts in each of those companies took the opportunity to mess with those innovative companies and spread false information because the opportunity to profit was believed to be easy. It's technical, and retail, shorts believe, is stupid.
It works better for small, not yet validated biotechs.
Shorts are a menace to the world. A person can legitimately short a portfolio holding. That's a reasonable way to manage the downside risk if they anticipate something they own was bought at too high a price or if there are macro events that will drive that value down.
But the shorts that manipulate markets and sentiment and spread false light narratives are criminals who leverage our constitutional protections to do harm to society and other investors for profit, spits and giggles.
Oh nonsense. They are all over the place as the microcap level. They are constantly being shorted and attacked by opportunists who think they can take them over like Martin Shkreli. And some have garbage and stay valued highly for years before they crash, because they are being milked by investment funds and their friends taking investor money and playing with them.
Your insight is really not very insightful.
And yeah, there was not an ecosystem developing the CDMO space for this exact product, and so she invested in other people creating it, and they sold, and she bought the retained expertise as part of her spinoff rights so that she could maintain the SAME company effectively, for manufacturing through approval.
But the company owns Flaskworks, and that is the obvious future. They also have the full economic control of Sawston except for those parts that will be used to meet their requirements for local regional development financing, which was low cost, but requires that they provide CDMO services to other, local researchers and companies at Cambridge and in that region.
But yeah, according to shorts it's all criminal even though they are top lawyers who had extremely responsible positions in government and could be making way more money doing other things, with no cares.
Such fricking idiocy. But yeah, it's in your economic interest to spread this nonsense. And of course, UCLA, doctors at top research institutions in immunotherapy including University of Pennsylvania and Brown University, don't agree with you. But you're the anonymous expert online telling people how it really is. Pffft! nonsense! Get lost.
They are likely to be approved. Assuming approval, they have done an immense job keeping their expenses low, their manufacturing scale-up costs low. They are not "dendreon" though the idiot shorts made that bet 10 years ago and they won't let go... but it's a bad bet. This technology is way better at every level, and is breakthrough. Companies do go bankrupt, with fantastic technology as well, and as I said, that is ALWAYS the risk in these small biotechs. ALWAYS. But the opportunity is that IF they succeed, they have the potential to become extremely valuable. Unlike others, I won't predict the market gets it on any event. But someone will, and that will likely transform the conversation. All IMHO.
Any small biotech can fail. They can also go from zero to billions. That is the whole point. But your scaremongering is empty. Expected and empty.